ropivacaine has been researched along with colforsin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brownlow, RC; Butterworth, JF; Cole, LR; Leith, JP; Prielipp, RC | 1 |
| Amodeo, FS; Brummett, CM; Hong, EK; Janda, AM; Lydic, R | 1 |
2 other study(ies) available for ropivacaine and colforsin
| Article | Year |
|---|---|
Bupivacaine inhibits cyclic-3',5'-adenosine monophosphate production. A possible contributing factor to cardiovascular toxicity.
Topics: Adenylyl Cyclases; Adult; Amides; Bupivacaine; Cardiovascular Diseases; Colforsin; Cyclic AMP; Drug Interactions; Enzyme Activation; Epinephrine; Female; GTP-Binding Proteins; Humans; Kinetics; Lymphocytes; Male; Mepivacaine; Middle Aged; Models, Biological; Receptors, Adrenergic, beta; Ropivacaine; Signal Transduction; Stimulation, Chemical | 1993 |
Perineural dexmedetomidine added to ropivacaine for sciatic nerve block in rats prolongs the duration of analgesia by blocking the hyperpolarization-activated cation current.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amides; Analgesia; Anesthetics, Local; Animals; Behavior, Animal; Colforsin; Cyclic Nucleotide-Gated Cation Channels; Dexmedetomidine; Dose-Response Relationship, Drug; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Hypnotics and Sedatives; Idazoxan; Male; Nerve Block; Pain Measurement; Potassium Channel Blockers; Potassium Channels; Prazosin; Pyrimidines; Rats; Rats, Sprague-Dawley; Ropivacaine; Sciatic Nerve | 2011 |